EVLO (Evelo Biosciences) EPS (Basic) : $-14.00 (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Evelo Biosciences EPS (Basic)?

Evelo Biosciences's basic earnings per share (Basic EPS) for the three months ended in Sep. 2023 was $-1.42. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2023 was $-14.00.

Evelo Biosciences's EPS (Diluted) for the three months ended in Sep. 2023 was $-1.42. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-14.00.

Evelo Biosciences's EPS without NRI for the three months ended in Sep. 2023 was $-1.33. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was -13.69.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Evelo Biosciences EPS (Basic) Historical Data

The historical data trend for Evelo Biosciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evelo Biosciences EPS (Basic) Chart

Evelo Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS (Basic)

Get a 7-Day Free Trial

-55.60

-53.40

-47.40

-46.20

-26.20

Evelo Biosciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EPS (Basic)	Get a 7-Day Free Trial															-5.66	-4.20	-4.60	-3.78	-1.42

Evelo Biosciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Evelo Biosciences's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-114.527	-	0)	/	4.358
	=	-26.28

Evelo Biosciences's Basic EPS for the quarter that ended in Sep. 2023 is calculated as

Basic EPS (Q: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-12.364	-	0)	/	8.692
	=	-1.42

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.00

Evelo Biosciences (OTCPK:EVLO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Evelo Biosciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Evelo Biosciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Evelo Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evelo Biosciences Inc (OTCPK:EVLO) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

620 Memorial Drive, 5th Floor, Cambridge, MA, USA, 02139

Website

https://www.evelobio.com

Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.

Executives

Simba Gill	director, officer: President & CEO	515 GALVESTON DR, REDWOOD CITY CA 94063
Mark Bodmer	officer: See Remarks	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Marella Thorell	officer: Chief Financial Officer	1226 CHARTER LANE, AMBLER PA 19002
Duncan Mchale	officer: Chief Medical Officer	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Alexander C Reynolds	director	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Horizon Technology Finance Corp	10 percent owner	312 FARMINGTON AVENUE, FARMINGTON CT 06032
Jeffrey R. Moore	director	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Ventures Fund Iv, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Robert L. Rosiello	director	400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Stephen J Carriere	officer: Principal Accounting Officer
David R Epstein	director	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Lord Ara Darzi	director	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Pioneering Fund Vii, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Tonya Williams	director	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139